Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018

Printer-friendly versionPDF version

Endometriosis Therapeutics Market is forecast to Show Steady Growth until 2018.The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders

GlobalData estimates that the global endometriosis therapeutics market was valued at $785m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 5.9% to reach $1,239m by 2018. This steady growth is primarily attributed to the recently launched product, Visanne (dienogest), and the expected launch of the pipeline product, Elagolix (NBI-56418), in 2015 in the US and Europe. Organizations such as the Endometriosis Special Interest Group (EndoSIG), through their work are increasing awareness about the disease among the general public. This increasing awareness and the resultant higher treatment seeking rates for the disease are also expectecd to contribute to the growth of the market. The current market is underserved due to the lack of specific as well as non-invasive diagnostic techniques, alongside low disease awareness and the poor safety and moderate efficacy profiles of the current marketed therapies. There is a high unmet need which is largely driven by the unavailability of products with adequate efficacy and safety profiles.
 
The current competition in the endometriosis therapeutics market is weak. The global market currently
has hormonal therapy as the mainstay for the treatment for endometriosis. At present, the treatment
options are limited to gonadotropin-releasing hormone (GnRH) agonists, progestins, and androgens, whose long term use is associated with undesirable side effects such as chronic pelvic pain, infertility, edema, changes in weight, migraines, depression, mood swings, nausea, hot flashes, breast enlargement/tenderness, changes in cervical erosion and cervical secretions, breakthrough bleeding and amenorrhea. All other drugs, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and oral contraceptives (OCs) are prescribed off-label by physicians. The currently available pharmacological and
surgical treatment options primarily target short term symptomatic relief with none of them capable of
treating the progression of the disease. Thus, the endometriosis therapeutics market has a high unmet
need for therapies with higher efficacy and better and long-term safety as well as for disease modifying
drugs. The market holds significant commercial potential for such novel therapies.
 
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Endometriosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=prpoi
 
GlobalData’s analysis shows that the endometriosis therapeutics developmental pipeline is weak with only 15 molecules in various phases of development, including six first-in-class molecules. These first-in-class molecules have a distinct advantage over the currently marketed products for endometriosis in terms of offering better symptomatic management but not with respect to treating the progression of the disease. The pipeline for endometriosis treatment includes GnRH antagonists, GnRH agonists, aromatase inhibitors (AIs), low-dose estrogen progestin, progesterone receptor selective blocker, steroid sulfatase inhibitor, neurokinin-3 (NK3) receptor antagonist, follicle stimulating hormone receptor (FSHR) negative allosteric modulator (NAM) and others. The small developmental pipeline for endometriosis may not be able to bring in any paradigm shift in the treatment of endometriosis during the forecast period, as most of the molecules with novel mechanism of action are in early phase of development, with only one molecule, NPC-01 (low-dose estrogen progestin), in Phase III of clinical development in Japan.
 
GlobalData, the industry analysis specialist, has released its new report, “Endometriosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global endometriosis therapeutics market and identifies the key trends shaping and driving it. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
 
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Endometriosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=prpoi
 
Visit our report store: http://www.globaldata.com/reportstore
 
For more details contact:
pressreleases@globaldata.com
            
North America:                 +1 646 395 5477
Europe:                                +44 207 753 4299
                                                +44 1204 543 533
Asia Pacific:                         +91 40 6616 6782